Study to Determine the Safety & Effectiveness of Dupilumab for Treatment

Updated 06/21/2024

Status Completed

Clinical Trial Summary

The primary objective of the study was to assess the efficacy of Dupilumab, compared to placebo, in adult patients with moderate-to-severe atopic dermatitis (AD).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01979016
Study type	Interventional
Source	Regeneron Pharmaceuticals
Contact
Status	Completed
Phase	Phase 2
Start date	December 31, 2013
Completion date	January 31, 2015

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03151148` - Targeted Microbiome Transplant in Atopic Dermatitis	Phase 1/Phase 2
	Active, not recruiting	`NCT05456529` - Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis	Phase 3
	Completed	`NCT04056130` - A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects	Phase 1
	Recruiting	`NCT04173442` - Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy
	Completed	`NCT05372653` - A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis	Phase 3
	Completed	`NCT03168113` - Atopic Dermatitis (AD) and Food Allergy	N/A
	Terminated	`NCT03389893` - Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis	Phase 4
	Recruiting	`NCT04541810` - A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
	Completed	`NCT02357940` - Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema	N/A
	Recruiting	`NCT05667623` - To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD	Phase 3
	Recruiting	`NCT05650320` - To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients With AD	Phase 3
	Withdrawn	`NCT04666675` - A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil	Phase 3
	Active, not recruiting	`NCT05959083` - Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis
	No longer available	`NCT04159597` - Expanded Access to Upadacitinib